CEPI – Coalition for Epidemic Preparedness Innovations [to 10 March 2018]
March 7, 2018
CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS
— First major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases —
[See Milestones above for more detail]
EDCTP [to 10 March 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
7 March 2018
Ninth EDCTP Forum: call for abstracts, scholarships and symposia opens
The Ninth EDCTP Forum will be held in Lisbon, Portugal, from 17 to 21 September 2018. The EDCTP Forum programme…
The theme of the Forum is Clinical research and sustainable development in sub-Saharan Africa: the impact of North-South partnerships.
Go to the Ninth EDCTP Forum website
European Medicines Agency [to 10 March 2018]
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5-8 March 2018
Immediate measures agreed for Zinbryta and Xofigo while reviews are ongoing; public hearing decided for quinolone and fluoroquinolone antibiotics
FDA [to 10 March 2018]
March 08, 2018 –
Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for oral testimony before the U.S. House Committee on Energy and Commerce Subcommittee on Oversight and Investigations hearing “Examining U.S. Public Health Preparedness for and Response Efforts to Seasonal Influenza.”
March 06, 2018 –
FDA approves new HIV treatment for patients who have limited treatment options
Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV)…
Gavi [to 10 March 2018]
08 March 2018
Gavi named amongst highest scorers in gender equality report
Global Health 50/50 release review of gender-related policies at 140 global health organisations.
Global Fund [to 10 March 2018]
Global Fund Welcomes New Report on Gender Equality
08 March 2018
The Global Fund to Fight AIDS, TB and Malaria applauded today’s release of the Global Health 50/50 Report, citing steep challenges in global health related to gender equality.
IVAC [to 10 March 2018]
Afghanistan takes important step to prevent a silent killer of children/Rotavirus vaccine for infants could prevent 12,000 deaths in the coming decade
By Lois Privor-Dumm and Dr. Ghulam Dastagir Nazary
MSF/Médecins Sans Frontières [to 10 March 2018]
MSF Response to New WHO Guidelines for HIV-Related Cryptococcal Disease
March 07, 2018
The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes the launch of updated guidance by the World Health Organization (WHO) this week on the diagnosis, treatment, and management of cryptococcal disease, an opportunistic infection mainly affecting people living with advanced stages of HIV/AIDS.
NIH [to 10 March 2018]
March 9, 2018
NIH experts call for transformative research approach to end tuberculosis
— TB is one of the oldest known human diseases and the leading infectious cause of death worldwide.
A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in the March 2018 issue of The American Journal of Tropical Medicine and Hygiene. In the article, authors Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Robert W. Eisinger, Ph.D., special assistant for scientific projects at NIAID, discuss the need to modernize TB research by applying new diagnostic, therapeutic, and vaccine approaches…
Monoclonal antibodies crucial to fighting emerging infectious diseases, say NIH officials
March 8, 2018 — Special antibodies have shown promise in the fight against cancer and autoimmune diseases.
Antiviral drug not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives
March 7, 2018 — NIH-funded study observes no significant reduction of infection rates at age 6 months.
High uptake and use of vaginal ring for HIV prevention observed in open-label study
March 6, 2018 — The HOPE study launched in 2016.
Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to an interim analysis of study data. In addition, the rate of HIV infection among participants in the open-label study, which has no placebo arm for comparison, is half of what might be expected in the absence of the ring, according to mathematical modeling that has significant limitations…
One-month tuberculosis prophylaxis as effective as nine-month regimen for people living with HIV
March 5, 2018 — Study results have the potential to dramatically change clinical practice.
UNAIDS [to 10 March 2018]
8 March 2018
Measuring homophobia to improve the lives of all
A new index to measure levels of homophobia that can show the impact that homophobia has on countries has been developed.
The new index, published in the European Journal of Public Health, combines both data on institutional homophobia, such as laws, and social homophobia—relations between people and groups of people.
UNICEF [to 10 March 2018]
Selected Press Releaases
UNICEF report: Over half a billion ‘uncounted’ children live in countries unable to measure SDG progress
NEW YORK, 7 MARCH 2018 – Early assessment of progress toward achieving the Sustainable Development Goals confirms an alarming lack of data in 64 countries, as well as insufficient progress toward the SDGs for another 37 countries where the data can be tracked.
[See Research, Reports below for more detail]
25 million child marriages prevented in last decade due to accelerated progress, according to new UNICEF estimates
NEW YORK, 6 March 2018 – The prevalence of child marriage is decreasing globally with several countries seeing significant reductions in recent years, UNICEF said today. Overall, the proportion of women who were married as children decreased by 15 per cent in the last decade, from 1 in 4 to approximately 1 in 5.
Wellcome Trust [to 10 March 2018]
News / Published: 9 March 2018
The story of a superbug from genome to advocacy
A ‘typhoid superbug’ in Pakistan has been in headlines around the world. Researchers identified a typhoid strain that has become resistant to multiple antibiotics. Elizabeth Klemm, one of those researchers, tells the story behind the headlines.
The genetic structure of a strain of the bacteria that causes typhoid which is resistant to five classes of antibiotics has been uncovered by scientists at the Wellcome Sanger Institute (opens in a new tab) with collaborators at Public Health England and Aga Khan University, Pakistan.
There is currently a major outbreak of this highly resistant typhoid fever in Pakistan, and there has been a single case in the UK following travel, which was isolated and treated.
This new study shows that the typhoid strain behind the outbreak has acquired an additional piece of DNA and so has become resistant to multiple antibiotics, including a third-generation antibiotic.
The results, published in mBio (opens in a new tab), suggest that treatment options are running out for typhoid, and there is an urgent need for more stringent preventative strategies including vaccines…
Sir John Sulston (1942-2018)
9 March 2018
We were deeply saddened to hear about the death of Sir John Sulston this week. John was an outstanding figure in UK biological and medical science and in Wellcome’s history.
For his remarkable work on the development of cells within the nematode worm C. elegans, he was rightfully recognised with the Nobel Prize in 2002.
But it was his leadership of the UK’s contribution to the Human Genome Project that was fundamental not only to the success of the project but also to the sequence being made freely available for all to use.
John’s close relationship with Wellcome began in the early 1990s when he was awarded the Trust’s biggest grant up to that point – £46.5m – to establish a genome sequencing centre at Hinxton near Cambridge. Over the next decade, he developed the Wellcome Trust Sanger Institute into one of the world’s leading centres for genome science.
John was adamant that the human DNA code should be released into the public domain so that other researchers could study and use it. This principle was adopted at the 1996 meeting of HUGO in Bermuda, and two years later John led the acceleration of the project – with funding from Wellcome to deliver one-third of the genome – to ensure that private interests did not threaten this accessibility.
The completion of the human genome in 2003 (a draft having been published in 2001) was a triumph for John, his team at the Wellcome Trust Sanger Institute, and the global community of researchers who worked on the project.
Eliza Manningham-Buller, Chair of Wellcome, said: “I am deeply saddened to hear of John’s death. His contribution to genetics was unparalleled and in setting up the Wellcome Sanger Institute he changed the course of genomics research. It was an honour to know him and sympathies go to his family.”
Jeremy Farrar, Director of Wellcome, said: “John was a brilliant scientist and a wonderful, kind and principled man. His leadership was critical to the establishment of the Wellcome Sanger Institute and the Human Genome Project, one of the most important scientific endeavours of the past century.
“His dedication to free access to scientific information was the basis of the open access movement, and helped ensure that the reference human genome sequence was published openly for the benefit of all humanity. It’s just one of the ways that John’s approach set the standard for researchers everywhere.”
9 March 2018
Sir John Sulston and the Human Genome Project
News 8 March 2018
8 projects to increase vital knowledge about women’s health
To mark International Women’s Day 2018, Charli Colegate from our Humanities & Social Science team highlights eight projects Wellcome is funding to explore the health experiences of women from different backgrounds around the world.
News 7 March 2018
Jeremy Farrar reappointed as Wellcome’s Director
Dr Jeremy Farrar, the Director of Wellcome, has been reappointed by Wellcome’s Board of Governors for a second five-year term.
Jeremy’s second term as Director will begin in October 2018 and run until 2023.
He joined Wellcome in 2013, succeeding Sir Mark Walport. Jeremy is a world-renowned clinical scientist and a leading figure in the field of infectious disease. Between 1996 and 2013, he was Director of the Oxford University Clinical Research Unit in Vietnam, which is supported by Wellcome…
DCVMN – Developing Country Vaccine Manufacturers Network [to 10 March 2018]
5 April 2018
Webinar: The new Future Vaccine Manufacturing Hub, collaborating with DCVMN
Prof Robin Shattock, Professor of Mucosal Infection and Immunity, Imperial College, London
Thursday, April 5, 2018 9:00 am
Europe Summer Time (Paris, GMT+02:00)
IFPMA [to 10 March 2018]
Global Health Matters
Vaccines: Reflecting on 2017 and what’s on the 2018 horizon
5 March 2018
By Laetitia Bigger
2017 has shown how the power of collaboration and partnership is vital in extending the benefits of vaccines to an ever-growing number of people. Let me take you through some of the key moments for vaccines in 2017 and look ahead to 2018…